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Background: Phantom limb pain is a prevalent condition that is difficult to manage, with a lack of robust evidence
to support the use of many adjunctive treatments. Acupuncture can be effective in the management of many painful
conditions but little is known about its effectiveness in treating phantom limb pain. The aim of this study is to explore the
feasibility of conducting a randomized controlled trial comparing acupuncture and routine care in a group of lower limb
amputees with phantom limb pain.
Methods/design: An unstratified, pragmatic, randomized, two-armed, controlled trial of parallel design comparing
acupuncture and usual care control will be conducted. A total of 20 participants will be randomly assigned to receive
either usual care or usual care plus acupuncture. Acupuncture will include eight 1 hour treatments delivered pragmatically
over 4 weeks by practitioners trained in traditional Chinese medicine. As outcome measures, the Numerical Pain Rating
Scale, short-form McGill Pain Questionnaire 2, EQ-5D-5 L, Hospital Anxiety and Depression Scale, 10-Item Perceived Stress
Scale, Insomnia Severity Index, and Patient Global Impression of Change will be completed at baseline, weekly for the
duration of the study and at 1 month after completion of the study. After completion of the trial, participants will provide
feedback though semi-structured interviews.
Feasibility will be determined through the ability to recruit to the study, success of the randomization process,
completion of acupuncture intervention, acceptability of random allocation and completion of outcome measures.
Acceptability of the acupuncture intervention will be determined through semi-structured interviews with participants.
The appropriateness of outcome measures for a future trial will be addressed through completion rates of questionnaires
and participant feedback.
Discussion: Data generated on effect size will be used for future sample size calculations and will inform the
development of an appropriate and feasible protocol for use in a definitive multicentre randomized controlled trial.
Trial registration: ClinicalTrials.gov: NCT02126436.
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Phantom limb pain, defined as painful sensations per-
ceived in the missing portion of the amputated limb [1],
was recorded medically as early as the sixteenth century
by Ambroise Paré [2]. It is very common and prevalence
may be as high as 75 to 80% [3,4].
Treatment of phantom limb pain includes such in-
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unless otherwise stated.interventions, neuromodulation and supportive non-
pharmacological or noninvasive techniques, such as
mirror therapy, graded motor imagery and stump
liners. Evidence suggests that pre-emptive epidural
and perineural analgesia might not prevent chronic
phantom limb pain [5,6]. Pre-emptive gabapentin has
also been found to be ineffective [7]. Pharmacological
interventions, including morphine, gabapentin and
ketamine, may provide short term analgesic efficacy
[8]. There is a lack of robust evidence to support the
use of neuromodulation [9], mirror therapy [10] orral. This is an Open Access article distributed under the terms of the Creative
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trolled trial suggested that stump liners might reduce
phantom limb pain [12] but the sample size in this
study was small.
Acupuncture has been shown to be an effective inter-
vention in the management of many pain conditions
[13-15] but little is known about the effectiveness of
acupuncture for the treatment of neuropathic pain [16].
Specifically, the effectiveness of acupuncture for treating
phantom limb pain has not been widely assessed or doc-
umented, with most of the literature consisting of case
reports [17,18]. Although these studies generally report
positive outcomes [17], they are at the bottom of the
hierarchy of evidence [19]. A systematic review including
English, Chinese and Korean databases identified only
two nonrandomized controlled trials evaluating the
effectiveness of acupuncture. Although these studies
reported positive outcomes, both were deemed to have a
high risk of bias and low methodological quality [20].
Further research is needed to evaluate the effectiveness
of acupuncture for treating phantom limb pain but,
prior to a definitive trial, a study is needed to determine
feasibility [21].
The objectives of this study are to: (1) explore the
feasibility of recruiting, randomizing and retaining par-
ticipants; (2) evaluate the feasibility and acceptability of
including a standard care control; (3) evaluate the adher-
ence or compliance and acceptability of acupuncture as
an intervention; (4) evaluate the appropriateness of out-
come measures and their completion rates and explore
participants’ experience in completing outcome mea-
sures; (5) identify appropriate primary and secondary
outcome measures that could be used in future trials; (6)
explore the perceived effectiveness of acupuncture in
treating phantom limb syndrome; (7) generate data on
effect size for use in future sample size calculations; and
(8) inform the development of an appropriate and feas-




A comparative effectiveness feasibility study will be con-
ducted, using a mixed-methods approach, including a
small randomized controlled trial and semi-structured
interviews. The randomized controlled trial will be an
unstratified, open, pragmatic, effectiveness trial, of paral-
lel design, with two arms, using balanced randomization
between acupuncture and usual care and a usual care
control. Cross-sectional interviews will be carried out at
the end of the intervention period.
Ethical approval was granted from the National Re-
search Ethics Service Committee London (Bloomsbury)
in July 2014 and Guy’s and St Thomas’ R & D andLondon South Bank University in October 2014. The
trial is registered with ClinicalTrials.gov (NCT02126436)
https://www.clinicaltrials.gov/ct2/show/study/
NCT02126436 and will be conducted in compliance
with the principles of the Declaration of Helsinki [22]
the London South Bank University Code of Practice, and
the London (Bloomsbury) Research Ethics Committee.
Study settings
The study will be conducted at the Amputee Rehabilitation
Unit, at Lambeth Community Care Centre, London, Guy’s
and St Thomas’ NHS Foundation Trust. The Amputee
Rehabilitation Unit is a 12-bed inpatient unit that provides
specialist rehabilitation after major amputation. It accepts
both primary and established amputees who have under-
gone a functional decline for approximately 7 weeks of
evidence-based care, including access to specialist medical,
nursing, therapy, and counselling professionals. Acupunc-
ture will be provided at the Gateway Acupuncture Clinic
(which is located in the same building) and provides an
NHS acupuncture service through GP referral, in the area
of Lambeth and Southwark. The clinic provides treatment
for chronic long-term conditions, specializing in chronic
pain, headaches, migraines and HIV.
Recruitment
Participants will be approached and recruited whilst they
are inpatients at the Amputee Rehabilitation Unit. Newly
admitted potential participants will be identified by clin-
ical staff (JG, CC), approached by the researcher (EGT),
initially screened, and provided with oral and written in-
formation. Participants who pass initial screening tests
and are willing to participate will have a final eligibility
check by EGT before enrolment in the study (Figure 1).
Signed, informed consent will be obtained from all par-
ticipants before enrolling them in the study. Those de-
clining to participate will be asked briefly for their
reasons. As the study is a feasibility study, no sample
size calculation has been performed [21]. An arbitrary
number of 20 participants was deemed adequate to pro-
vide information on recruitment, randomization and ac-
ceptability of acupuncture and answer the objectives of
this trial [23].
Eligibility criteria
Participants will be included if they: (1) at least 18 years
of age, (2) have full cognitive ability and are able to com-
municate in English, (3) have traumatic or medical am-
putation of a lower limb (greater than toes), and (4) are
currently experiencing phantom limb pain of ≥5 on an
11-point verbal rating scale (that is, moderate or severe
phantom limb pain) [24]. Participants will be excluded if
they: (1) have congenital limb absence, (2) are medically
too unwell (as advised by medical staff at the Amputee
Figure 1 Participants’ flow through the study. The different phases of the study and participants’ flow through the study with details on timings
of the different phases of the study. ARU, Amputee Rehabilitation Unit; GP, general practitioner; HADS, Hospital Anxiety and Depression Scale; ISI,
Insomnia Severity Index; NPS, numerical pain scale; PGIC, Patient Global Impression of Change; PSS-10, 10-Item Perceived Stress Scale; SF-MPQ-2,
short-form McGill Pain Questionnaire 2.
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puncture is cautioned, including participants with poorly
controlled epilepsy, severe haemophilia or other bleeding
or clotting disorders, or a pacemaker (if using electro-
acupuncture), and patients undergoing or who have
recently undergone chemotherapy or bone marrow
transplant, any skin changes or removal of lymph nodes
in the body, that would preclude placement of acupunc-
ture needles [25].Intervention (RCT)
The acupuncture group (group A) will receive usual in-
patient care and a course of acupuncture. The control
group (group C) will receive usual inpatient care only.
Usual care will include both medical intervention and
daily physiotherapy and rehabilitation, as routinely pro-
vided at the Amputee Rehabilitation Unit.
All acupuncture practitioners involved in the study
will be trained in the practice of traditional Chinese
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Acupuncture Council, will have at least 15 years clinical ex-
perience and will follow the safety guidelines of the British
Acupuncture Guide to Safe Practice [25]. Acupuncture nee-
dles will be single-use, presterilized, disposable, solid, stain-
less steel needles (with prepacked single-use guide tubes if
guide tubes are used). The acupuncture intervention will be
pragmatic but will be guided by a protocol previously devel-
oped though a Delphi practitioner consensus study [26].
This protocol advises:
 Using a combination of body and auricular
acupuncture;
 Treating the contralateral limb and possibly the
ipsilateral limb;
 Including auricular acupuncture points such as shen
men, sympathetic and points corresponding to the
lower limb;
 Depending on the health of the tissue and the
individual participant, needling around the stump;
 Mirroring local and distal points by needling the
opposite limb;
 Including points on the lower back (taking a
segmental approach to dermatomal pain);
 Including points such as LI4 + LR3, LR3, GV20,
SP10 and also specified points according to
participants’ specific symptoms;
 Retaining needles for 20 to 30 minutes.
No set criteria will be followed when needling, other than
to follow the guidelines of the protocol. Practitioners will
assess and treat participants under the paradigm of trad-
itional Chinese medicine. Treatment may (depending on
the practitioner’s diagnosis and treatment plan) include
electro-acupuncture or other adjunctive interventions, such
as cupping. All participants in group A will receive eight
one-hour acupuncture sessions (twice weekly for 4 weeks)
delivered during their inpatient stay.
Withdrawals, discontinuation and post-trial care
Acupuncture is a low-risk intervention and any adverse
effects are usually minimal and temporary. In the event
of mild adverse effects (drowsiness, haematoma, bleed-
ing from a point, stuck needle, pain after needling a
point) participants will not be withdrawn but will be able
to drop out if they so wish. In the event of the occur-
rence of more serious adverse events, participants will
be withdrawn. As evidence suggests that acupuncture is
a safe treatment [27,28] and as this study is not assessing
effectiveness, no specific arrangements have been made
to review interim safety and effectiveness. However, in
the event of three participants reporting prolonged ag-
gravation of pain or other potential serious adverse
events, the trial will be stopped prematurely. Aftercompletion of the study, participants will be offered ac-
cess to acupuncture through their general practitioner
or physiotherapist.
Concomitant care
Participants will be asked to refrain from using other
forms of complementary therapy for the duration of the
trial but may receive any intervention as routinely pre-
scribed by clinical staff at the Amputee Rehabilitation
Unit.
Study restrictions
Participants and practitioners will be asked not to dis-
close participant allocation to the researcher (EGT).
Intervention (interviews)
Consecutive sampling will be used to recruit (n = 5) par-
ticipants from group A to explore their experience of
being in the trial, having acupuncture and completing
outcome measures. Participants will be interviewed once
after completion of the study. Semi-structured inter-
views will be facilitated by EGT, will follow a topic guide
(Additional file 1) and will be recorded and transcribed
verbatim.
Randomization, allocation concealment and blinding
Randomization and allocation concealment will be used
to ensure against selection bias [29]. Prior to commence-
ment of the study, a researcher (NR) not involved in the
day-to-day execution of the study will randomly allocate
and conceal allocation. A copy of the randomized se-
quence will be kept in a locked cabinet and not shared
with study personnel. The researcher (EGT) who will
enrol participants and assign them to either acupuncture
intervention or control will not know the random se-
quence or treatment allocation.
Randomization will be achieved using a computer-
generated random numbers table and will be unstratified
and balanced (1:1). Permuted blocking will be used to
achieve balance between study arms. A block size of four
will be used in this study. Allocation concealment will
be implemented using sequentially numbered, opaque
sealed envelopes. The envelopes will be opened sequen-
tially only after participant’s details are written on each
envelope.
Participants and practitioners involved in the study
will not be blinded. However, the researcher collecting
outcome measures (EGT) will be blind to the partici-
pant’s allocation.
Outcome measures
Recommendations from the Assessment Committee of the
Neuropathic Pain Special Interest Group [30] and the Ini-
tiative on Methods, Measurements, and Pain Assessment
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developing outcome measures for use in this trial.
The primary outcome measure will be an 11-point nu-
merical rating scale to record pain intensity. Pain will be
rated by a number describing average pain over the previ-
ous week, using the anchors 0, meaning ‘no pain’, and 10,
meaning ‘pain as bad as you can imagine’ [31]. The
numerical rating scale is an appropriate measure of pain
intensity [32] and is a recommended outcome measure for
clinical trials of chronic pain treatment effectiveness [31].
Secondary outcome measures will include a numerical
rating scale measuring ‘worst’ pain, the short-form McGill
Pain Questionnaire 2 (SF-MPQ-2), EQ-5D-5 L, Hospital
Anxiety and Depression Scale, 10-Item Perceived Stress
Scale, Insomnia Severity Index, and Patient Global Impres-
sion of Change.
The McGill Pain Questionnaire and its short form
(SF-MPQ) are generic questionnaires (applicable to any
pain), whose reliability and validity have been exten-
sively documented [33]. The SF-MPQ-2 is a 22-item
questionnaire that uses a 10 point rating scale and re-
cords the major symptoms of both neuropathic and
non-neuropathic pain [34]. It is reliable and valid for
measuring diverse chronic pain [35].
The EQ-5D measures health-related quality of life and
although not validated for use in neuropathic trials, re-
sults appear robust in neuropathic trials with a large
sample size or when recording a large-pain relief re-
sponse in the active group [30]. The EQ-5D-5 L has the
same core dimensions as the EQ-5D but instead of a
three-point rating scale it uses five levels.
The Hospital Anxiety and Depression Scale measures
emotional function and is responsive to change in
neuropathic pain clinical trials [30]. It includes seven de-
pression and seven anxiety items to cover cognitive and
emotional aspects of depression and anxiety and is reli-
able and valid for assessing emotional distress in a med-
ical population [36].
The Perceived Stress Scale is a 4-, 10- or 14-item ques-
tionnaire that was designed to measure psychological stress
[37]. It is reliable and valid and was found to have accept-
able psychometric properties across 19 studies [38]. The
10-item version has no loss of psychometric quality, com-
pared with the 14-item version [39] and has, in fact, been
shown to be superior [38].
The Insomnia Severity Index measures perception of
insomnia and the degree of concerns or distress caused
by insomnia; it consists of seven items [40]. It has the
advantage of measuring symptoms over a 2-week period
and is recommended when insomnia is a secondary end-
point. It has been validated against both polysomno-
graphic and prospective sleep diary measures [40,41].
The Patient Global Impression of Change scale is ad-
vised for use in clinical trials [30,31] and provides areadily interpretable assessment of participants evaluation
of the importance of their improvement [42]. The scale
used in this study will be a seven-point scale that ranges
from ‘no change or worse’ to ‘a great deal better’ [43].
Assessment
Participants will complete the questionnaires and rating
scales six times in total. Data for all items (except the
Patient Global Impression of Change, data for which will
only be collected from the end of week one) will be col-
lected at the time of enrolment and at the end of each
week for the duration of the study. The primary end-
point will be at the end of the intervention (end of week
4). Data for the outcome measures will also be deter-
mined one month after completion of the study. Ques-
tionnaires and rating scales will be completed under the
supervision of the researcher (EGT) at baseline and dur-
ing weeks 1 to 4 (whilst participants are inpatients at the
Amputee Rehabilitation Unit), and will be posted to par-
ticipants one month after completion of the study.
Analysis
As this is a feasibility study, emphasis will be on feasibil-
ity and not on statistical significance of results [21].
Compliance with the protocol will be examined through
number counts on drop outs or numbers of missed
treatments, completion rates of outcome measures, and
their perceived appropriateness and deviation from the
protocol. Data will be collected on the use of rescue
medication and adverse events (captured through open-
ended prompts by practitioners at each intervention
time point). Details of any participants who are excluded
from the study will be reported and exclusion will be
distinguished from attrition.
All statistical analysis will be undertaken using SPSS
Version 21 software. The analysis will test for within-
patient and between-group differences in measurements
taken at the beginning of the study, during the study, at
the end of the study and one month after completion of
the study. An intention-to-treat approach will be taken
[44]. To include missing data, any missing data will be
imputed using the last observation carried forward [45].
The null hypothesis is that there is no difference in
change in the primary outcome measure between group
A and C at the end of intervention (end of week 4).
Statistical analysis will be performed to verify rejection
of the null hypothesis with a P = 0.05 taken as indica-
tive of statistical significance. Nonparametric tests will
be used in inferential analysis. The nonparametric
Mann–Whitney U test will be used for analysis be-
tween groups. The difference between baseline and last
observation scores will be analyzed using Wilcoxon
signed-rank test. The effect size (Cohen’s d) will be calcu-
lated to provide information on the relative magnitude of
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treated in the same way as the primary outcome. Categor-
ical and continuous baseline characteristics will also be ana-
lyzed to test for between-group differences.
A framework analysis procedure [47] will be used to
analyze qualitative data. NVivo 10 software will be used to
develop the analytic framework and index transcripts.
Microsoft Excel will be used during charting. Interviews
will be transcribed verbatim. Specific steps will be followed
during data analysis, including; familiarization, coding,
identifying an analytic framework, indexing, charting and
mapping or interpretation. To ensure credibility, peer
debriefing will take place throughout the research process.
To ensure dependability, two researchers will separately
code a selection of transcripts.
The trial will be considered successful if:
 Recruitment rate is ≥2 participants per month fitting
the eligibility criteria.
 The study recruits ≥70% of all eligible potential
participants.
 Of the participants recruited to group A, ≥90%
receive their first acupuncture treatment within one
week of recruitment.
 After randomization and allocation, ≥90% of
participants receive treatment as initially intended.
 Of the participants recruited to group A, ≥80%
receive all eight acupuncture treatments.
 Of the participants recruited to group C, ≤10% drop
out of the study.
 At the primary endpoint of the study, questionnaires
and rating scales for outcome measures are
completed by ≥90% of participants.
 At one month after completion of the study,
questionnaires and rating scales for outcome
measures are completed by ≥60% of participants.
 Qualitative data identifies that outcome measures
are acceptable and appropriate, that questionnaires
and rating scales are easy to complete and that
outcome measures can be identified for used in a
definitive trial.
 Qualitative data implies that acupuncture is an
acceptable and effective intervention for treating
phantom limb pain with or without other secondary
symptoms.
 Qualitative and quantitative data implies that the
acupuncture protocol used in the feasibility study is
appropriate for use in a definitive multicentre
randomized controlled trial.
Data management and reporting
The Consolidated Standards of Reporting Trials (CON-
SORT) [48] and Standards for Reporting Interventions
in Clinical Trials of Acupuncture (STRICTA) [49] willbe adhered to when reporting. Data will be stored se-
curely with no participant identifiers included. Access to
and handling of data will be restricted to those involved
in the study. All disseminated findings will contain no
participant-identifiable data.
Discussion
Currently, no genuine placebo-controlled acupuncture
trials exist [50]. Different types of sham acupuncture
have been implemented in acupuncture trials, including;
shallow needling of acupuncture points, using nonpene-
trating needles, needling non-acupuncture points and
needling acupuncture points that are not indicated for
that specific condition, but none of these methods is
physiologically inert [50] and sham acupuncture might
have some level of effectiveness [51]. Therefore, despite
a lack of blinding introducing ascertainment bias, sham
acupuncture will not be used in this study and will not
be used in a future definitive trial.
Inferential statistical analysis and hypothesis testing
will be completed only to pilot procedure and will not
be interpreted as a measure of effectiveness of acupunc-
ture. Effectiveness will only be established after comple-
tion of a fully powered randomized controlled trail.
Results of this study will be disseminated through
publication.
Trial status
Recruitment commenced in October 2014 and it is an-
ticipated that it will finish by October 2015.
Additional file
Additional file 1: Summary of the interview topic guide. This guide
will be used to interview participants in the acupuncture group after
completion of the randomized controlled trial. PLP, phantom limb pain.
Abbreviation
SF-MPQ-2: short-form McGill Pain Questionnaire 2.
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